Abstract
Background. An incidence of premature ejaculation (PE) in men of reproductive age of 24–45 years is 23 %. The treatment of PE is based on antidepressants from the group of selective serotonin re-uptake inhibitors. However, drugs of this group have gametotoxic action. Objective . Evaluate the effectiveness of Neurodoz biocomplex, its effect on the parameters of spermogram and sperm DNA integrity in patients with PE. Materials and methods. The study involved 16 patients with PE and normozoospermia aged from 26 to 35 years. Ejaculate and sperm DNA fragmentation were assessed by Halosperm (Halotech®) method before and after the therapy. Duration of treatment was 2 months. Evaluation of efficacy was based on the duration of sexual intercourse, as well as on the visual analogue scale and the questionnaire data of patients with premature ejaculation. Results. In 8 weeks there was a decrease in ejaculate volume from to 3.6 ± 1.1 down to 3.2 ± 1.1 mL (p = 0.312) and an increase in the concentration of sperm (34.2 ± 9.8) × 106 up to (35.6 ± 9.7) × 106 (p = 0.688). Sperm motility (category a + b) increased from 36.6 ± 4.3 to 37.2 ± 4.5 % (p = 0.703), the percentage of morphologically normal forms increased from 14.6 ± 1.4 up to 14.8 ± 1.1 (p = 0.656). DNA fragmentation of sperm has decreased from 15.6 ± 2.7 down to 15.4 ± 2.7 % (p = 0.635). Duration of intravaginal latency increased from 101.8 ± 34.4 (45–150) up to 217.3 ± 28.9 (190–280) sec (p < 0.001). An overall score according to the premature ejaculation questionnaire decreased from 13.9 ± 3.0 (9–20) down to 4.4 ± 1.9 (0–7) (p < 0.001). Visual analogue scale symptoms improved from 7.3 ± 1.7 (5–10) to 2.6 ± 1.2 (0–4) (p < 0.001). Conclusion. Neurodoz is an effective and safe agent for PE correction. Giving an absence of negative impact of biocomplex on spermatogenesis in patients with normozoospermia, it is possible to administer it to men who are trying to conceive. Further study is necessary in order to assess an impact of the drug on semen parameters in subfertile patients
Highlights
An incidence of premature ejaculation (PE) in men of reproductive age of 24–45 years is 23 %
Ejaculate and sperm DNA fragmentation were assessed by Halosperm (Halotech®) method before and after the therapy
In 8 weeks there was a decrease in ejaculate volume from to 3.6 ± 1.1 down to 3.2 ± 1.1 mL (p = 0.312) and an increase in the concentration of sperm (34.2 ± 9.8) × 106 up to (35.6 ± 9.7) × 106 (p = 0.688)
Summary
1А; 2ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава России; Россия, Москва, 125284, 2-й Боткинский проезд, 3. Цель работы – оценить эффективность биокомплекса Нейродоз, его влияние на параметры спермограммы и целостность структуры ДНК сперматозоидов у пациентов с ПЭ. Исследование эякулята и оценку процента фрагментации ДНК сперматозоидов методом Halosperm (Halotech®) выполняли до и после терапии. Оценку эффективности терапии проводили по длительности полового акта, а также по визуальной аналоговой шкале и анкете диагностики ПЭ. Через 8 нед терапии биокомплексом Нейродоз было отмечено уменьшение объема эякулята с 3,6 ± 1,1 до 3,2 ± 1,1 мл (p = 0,312) и увеличение концентрации сперматозоидов с (34,2 ± 9,8) × 106 до (35,6 ± 9,7) × 106 (p = 0,688). Ключевые слова: преждевременная эякуляция, Нейродоз, ДНК-фрагментация сперматозоидов, спермограмма, дофамин, серотонин, тирозин, фенилаланин, 5-гидрокситриптофан
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
